COAG: A Rare Disease Registration Option Priced Entirely on an Unproven Safety Window
Strong data, zero competition, $430M in cash — and still overpriced at $25.
The Disease: Why GT Matters
Glanzmann thrombasthenia (GT) is a genetic disorder where platelets can’t clump together because a critical surface receptor is missing. About 5,000-10,000 patients worldwide. They bleed — spontaneously, after minor injuries, during surgery, during childbirth — and the only options today are reactive: transfuse platelets or inject clotting factors after the bleeding has already started. There is no approved preventive therapy. None. Not one.
Hemab’s lead drug, sutacimig, is a bispecific antibody designed to change this. One arm extends the half-life of activated clotting Factor VIIa in the blood; the other arm binds TLT-1, a receptor found only on activated platelets. The idea is to concentrate pro-coagulant activity at the bleeding site rather than systemically. In Phase 2, the best dose group showed an 87% reduction in annualized treated bleed rate and a 100% reduction in high-intensity bleeds requiring transfusion or surgery.
The FDA has granted sutacimig Breakthrough Therapy Designation, Fast Track, and Orphan Drug Designation — the full trifecta of regulatory acceleration for rare diseases.
The Problem: On-Target Toxicity
Any drug that enhances clotting carries an inherent pharmacological contradiction: it might also cause pathological blood clots. This isn’t a random side effect — it’s on-target toxicity, meaning the same mechanism that stops bleeding could trigger thrombosis.
In Phase 2 (N=34), the highest dose group (0.9 mg/kg) produced one case of deep vein thrombosis. That dose was suspended. D-dimer elevation — a biomarker of active clotting — was reported in 18% of patients. In the lower dose range planned for Phase 3 (0.3-0.6 mg/kg), roughly 29 patients had zero thrombotic events.
But 29 patients is not enough. The Rule of Three says that with zero events in 29 observations, the 95% confidence upper bound for the true event rate is still ~10%. You cannot rule out a clinically meaningful thrombotic risk from this sample size.
Whether a viable safety window exists — a dose range where sutacimig effectively prevents bleeding without causing clots — is the single variable that determines COAG’s entire investment value.
Precedent: Thrombosis Doesn’t Kill Approval
Three recent pro-coagulant drugs went through thrombotic events and still got approved:
Emicizumab (Hemlibra, Roche): Thrombotic microangiopathy at 0.8%, thrombosis at 0.5% overall; much higher in patients co-administered aPCC. Approved with a black box warning. 2022 global sales exceeded $4.3 billion.
Fitusiran (Sanofi): One fatal cerebral venous sinus thrombosis in Phase 2 triggered a clinical hold. Dose regimen was revised. Approved in 2025 with a black box warning.
Concizumab (Novo Nordisk): Three non-fatal thrombotic events suspended three trials. FDA issued a Complete Response Letter. Approved in 2024.
The pattern is clear: the FDA does not reject pro-coagulant drugs simply because thrombosis occurs. What matters is whether the dose-response relationship is manageable, whether monitoring protocols exist, and whether the unmet need justifies the benefit-risk tradeoff.
Sutacimig has a structural advantage over these precedents: GT patients generally don’t co-administer bypass agents (aPCC/rFVIIa), which were the primary thrombotic triggers for emicizumab and fitusiran. The external risk factors are lower in this patient population.
Why GT Is the Valuation Anchor, Not VWD
Hemab’s second asset, HMB-002, targets Von Willebrand Disease (VWD) — a much larger market (~120,000 patients). But HMB-002 is Phase 1/2 with only proof-of-mechanism data (VWF/FVIII levels rose 1.5x after single doses). That’s biomarker movement, not clinical proof that patients actually bleed less.
More importantly, VWD already has competition. Star Therapeutics’ VGA039 holds four FDA designations and is already in Phase 3, likely 2-3 years ahead of HMB-002.
GT is the opposite: zero competitors, extreme unmet need, strong efficacy signal, triple FDA designation. In rare disease investing, clinical de-risking matters more than market size. GT is small but clean; VWD is large but crowded. COAG’s value is sutacimig in GT. Everything else is optionality.
Valuation: Cash Floor + Pipeline Options
COAG is pre-revenue. No earnings, no margins, no multiples to anchor on. The correct framework is cash floor plus unit-level risk-adjusted NPV.
Cash: ~$425-435M at IPO closing, but cash is a wasting asset burning at $80-110M/year. By the time Phase 3 safety data reads out (18-24 months), roughly $260-315M remains — about $5.5-6.5/share.
Sutacimig GT: Peak sales of $250-350M (700-1,000 treated patients at $300-400K/year orphan pricing), net of 5-12% royalty stacking owed to Novo Nordisk and Genmab. At 50% margins, 9x operating profit multiple, and a ~0.55 time discount factor, success-state NPV is roughly $650-800M. At 50% probability of success, GT contributes about $7-8/share.
Everything else: FVII (~$0.7), HMB-002 VWD (~$0.8), preclinical (~$0.1), minus governance/license/tax drag (~$1.4). Net contribution: roughly $0.2/share.
Total probability-weighted EV: ~$13-15/share. The stock trades at $25.
What RA Capital’s Behavior Tells You — and Doesn’t
RA Capital is Hemab’s largest pre-IPO shareholder and holds a board seat. After the IPO, they did something notable: they continuously bought shares in the open market from May 5-11 at $24-25, on top of participating in the greenshoe at $18. Total post-IPO position: ~6.37M shares, roughly 13.6% of basic shares outstanding.
RA Capital manages $12.6 billion, employs 65+ scientific PhDs, and has delivered ~28.4% annualized returns since inception. As a board member, they have access to the complete Phase 2 dataset, PK/PD models, and internal FDA interaction discussions that public market investors do not.
Their continued buying likely reflects higher confidence in the safety window than public data alone can support. It may also reflect M&A optionality that our valuation framework essentially ignores — Novo Nordisk has a right of first negotiation on sutacimig, and a monopoly GT asset would be a natural strategic acquisition target.
But institutional behavior is not valuation evidence. RA Capital has deep sunk costs and reputational stakes in Hemab. Their open market purchases (~$5.1M) represent only 3.2% of their total position. And they can be wrong. The signal is real but should inform your monitoring, not your price.
The Buy Point
My framework: Buy point = post-burn remaining cash + pipeline expected value / 2.
Cash gets full credit because it’s hard. Pipeline gets half credit because the probability of success is itself uncertain — even after one round of probability-weighting, the PoS estimate spans 25-70%.
Current state (safety window and FDA design both unconfirmed):
Cash at decision gate: ~$6.0/share
Pipeline EV: ~$8.3/share
Buy point ≈ $6.0 + $8.3/2 ≈ $10/share. Range: $9-11.
At $10, you’re paying full price for cash and half price for the pipeline. Even if the pipeline’s expected value is overstated by 2x, the cash floor limits your downside.
This buy point is dynamic:
FDA confirms single-arm design → pipeline EV rises to ~$10, buy point shifts to ~$11
FDA design confirmed + early safety data clean → pipeline EV rises to ~$14-16, discount narrows to /1.5 (higher information quality), buy point shifts to $14-18
Thrombotic events in Phase 3 → pipeline EV collapses to $3-5, buy point drops to $7-8
Current price of $25 is roughly 2.5x the buy point. The market is prepaying for a base case that hasn’t been underwritten yet.
Bottom Line
COAG is not a bad company. The GT opportunity is real — zero competition, strong efficacy, long cash runway, favorable regulatory precedent for pro-coagulant drugs with manageable thrombotic risk. But the stock at $25 is pricing in outcomes that depend on a single unresolved variable: whether sutacimig’s safety window holds up in a larger, longer trial.
The honest answer is that nobody — not us, not RA Capital, not Hemab’s management — knows the true thrombotic rate at the target dose with sufficient statistical confidence. That uncertainty is not a flaw in the analysis; it’s the fundamental characteristic of the asset.
Pay full price for certainty. Pay half price for uncertainty. At $9-11, the pipeline is a free option on top of cash. At $25, you’re the one writing the option.